China’s CoronaVac is showing mere 50.4 percent efficacy in late-stage trials taking place in Brazil — far lower than earlier projections and barely enough to gain regulatory approval.
The new data, reported by researchers on Tuesday, is a big blow to the South American country as it weathers a second wave of one of the largest COVID-19 outbreaks worldwide.
The Beijing-made inoculation from Sinovac is just one of two vaccines that have been approved for trials by Brazilian authorities, the outlet reported.
Last week, researchers in Brazil celebrated results showing a much higher efficacy rate of 78 percent against “mild to severe” COVID-19 cases, but didn’t disclose there was a group of people who received the vaccine and still developed “very mild” infections.
The latest data includes that group, according to Richard Palacios, medical director for clinical research at Sao Paulo’s Butantan biomedical center.
Palacios and government officials insisted the data was still good news, because none of the